Merck KgaA's Daejeon, South Korea life science production site (Credit: Merck KgaA website)

As Mer­ck KGaA grows South Ko­re­an foot­print, it al­so ze­roes in on re­gion­al man­u­fac­tur­ing

Mer­ck KGaA is look­ing to fur­ther boost its ca­pac­i­ty in South Ko­rea as bio­phar­ma com­pa­nies eye to lo­cal­ize pro­duc­tion and tight­en their sup­ply chains in the Asia-Pa­cif­ic re­gion.

“We go where our cus­tomers are go­ing… APAC is now the place where we need to de­vel­op lo­cal ca­pa­bil­i­ties so that we are less sen­si­tive to all geopo­lit­i­cal ten­sions that may arise,” said Ivan Donzelot, Mer­ck KGaA’s head of in­te­grat­ed sup­ply chain op­er­a­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.